drugset / Trial / NCT01016769
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Phase 1/2
Completed
48 enrolled
Memorial Sloan Kettering Cancer Center
NATL COMP CA NETWORK · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out the good and bad effects that occur when temsirolimus is added to standard chemotherapy with carboplatin and paclitaxel.
Timeline
- Start
- 2009-11
- Primary completion
- 2018-06
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 1.5 unknown | Intravenous |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Temsirolimus | Small molecule | 15 mg | Intravenous |
| Subject | Temsirolimus | Small molecule | 20 mg | Intravenous |
| Subject | Temsirolimus | Small molecule | 25 mg | Intravenous |